UUUzodinma N. Uche

Uzodinma N. Uche

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Uzodinma N. Uche has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Downregulation of PIK3IP1/TrIP on T cells is controlled by TCR signal strength, PKC, and metalloprotease-mediated cleavage

    by Benjamin M. Murter, Sean C. Robinson, Hridesh Banerjee, Louis Lau, Uzodinma N. Uche, Andrea L. Szymczak-Workman, Lawrence P. Kane


  • Open Access

    Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types

    by Hem R. Gurung, Amy J. Heidersbach, Martine Darwish, Pamela Pui Fung Chan, Jenny Li, Maureen Beresini, Oliver A. Zill, Andrew Wallace, Ann-Jay Tong, Dan Hascall, et al.

    The broad application of precision cancer immunotherapies is limited by the number of validated neoepitopes that are common among patients or tumor types. To expand the known repertoire of shared neoantigen–human leukocyte antigen (HLA) complexes, we developed a high-throughput platform that coupled an in vitro peptide–HLA binding assay with engineered cellular models expressing individual HLA alleles in combination with a concatenated transgene harboring 47 common cancer neoantigens. From more than 24,000 possible neoepitope–HLA combinations, biochemical and computational assessment yielded 844 unique candidates, of which 86 were verified after immunoprecipitation mass spectrometry analyses of engineered, monoallelic cell lines. To evaluate the potential for immunogenicity, we identified T cell receptors that recognized select neoepitope–HLA pairs and elicited a response after introduction into human T cells. These cellular systems and our data on therapeutically relevant neoepitopes in their HLA contexts will aid researchers studying antigen processing as well as neoepitope targeting therapies.


  • Open Access

    Noncanonical STAT3 activity sustains pathogenic Th17 proliferation and cytokine response to antigen

    by Catherine H. Poholek, Itay Raphael, Dongwen Wu, Shankar Revu, Natalie Rittenhouse, Uzodinma U. Uche, Saikat Majumder, Lawrence P. Kane, Amanda C. Poholek, Mandy J. McGeachy

    The STAT3 signaling pathway is required for early Th17 cell development, and therapies targeting this pathway are used for autoimmune disease. However, the role of STAT3 in maintaining inflammatory effector Th17 cell function has been unexplored. Th17ΔSTAT3 mice, which delete STAT3 in effector Th17 cells, were resistant to experimental autoimmune encephalomyelitis (EAE), a murine model of MS. Th17 cell numbers declined after STAT3 deletion, corresponding to reduced cell cycle. Th17ΔSTAT3 cells had increased IL-6–mediated phosphorylation of STAT1, known to have antiproliferative functions. Th17ΔSTAT3 cells also had reduced mitochondrial membrane potential, which can regulate intracellular Ca2+. Accordingly, Th17ΔSTAT3 cells had reduced production of proinflammatory cytokines when stimulated with myelin antigen but normal production of cytokines when TCR-induced Ca2+ flux was bypassed with ionomycin. Thus, early transcriptional roles of STAT3 in developing Th17 cells are later complimented by noncanonical STAT3 functions that sustain pathogenic Th17 cell proliferation and cytokine production.


  • Open Access

    PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt

    by Uzodinma U. Uche, Ann R. Piccirillo, Shunsuke Kataoka, Stephanie J. Grebinoski, Louise M. D’cRuz, Lawrence P. Kane

    Phosphatidylinositol-3 kinases (PI3Ks) modulate cellular growth, proliferation, and survival; dysregulation of the PI3K pathway can lead to autoimmune disease and cancer. PIK3IP1 (or transmembrane inhibitor of PI3K [TrIP]) is a putative transmembrane regulator of PI3K. TrIP contains an extracellular kringle domain and an intracellular domain with homology to the inter-SH2 domain of the PI3K regulatory subunit p85, but the mechanism of TrIP function is poorly understood. We show that both the kringle and p85-like domains are necessary for TrIP inhibition of PI3K and that TrIP is down-modulated from the surface of T cells during T cell activation. In addition, we present evidence that the kringle domain may modulate TrIP function by mediating oligomerization. Using an inducible knockout mouse model, we show that TrIP-deficient T cells exhibit more robust activation and can mediate clearance of Listeria monocytogenes infection faster than WT mice. Thus, TrIP is a negative regulator of T cell activation and may represent a novel target for immune modulation. Graphical Abstract


  • Top Cited Papers
    Open Access

    Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection

    by Radha Gopal, Leticia Monin, Samantha Slight, Uzodinma Uche, Emmeline Blanchard, Beth A. Fallert Junecko, Rosalio Ramos-Payan, Christina L. Stallings, Todd A. Reinhart, Jay K. Kolls, et al.

    Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects one third of the world's population. Among these infections, clinical isolates belonging to the W-Beijing appear to be emerging, representing about 50% of Mtb isolates in East Asia, and about 13% of all Mtb isolates worldwide. In animal models, infection with W-Beijing strain, Mtb HN878, is considered “hypervirulent” as it results in increased mortality and causes exacerbated immunopathology in infected animals. We had previously shown the Interleukin (IL) -17 pathway is dispensable for primary immunity against infection with the lab adapted Mtb H37Rv strain. However, it is not known whether IL-17 has any role to play in protective immunity against infection with clinical Mtb isolates. We report here that lab adapted Mtb strains, such as H37Rv, or less virulent Mtb clinical isolates, such as Mtb CDC1551, do not require IL-17 for protective immunity against infection while infection with Mtb HN878 requires IL-17 for early protective immunity. Unexpectedly, Mtb HN878 induces robust production of IL-1β through a TLR-2-dependent mechanism, which supports potent IL-17 responses. We also show that the role for IL-17 in mediating protective immunity against Mtb HN878 is through IL-17 Receptor signaling in non-hematopoietic cells, mediating the induction of the chemokine, CXCL-13, which is required for localization of T cells within lung lymphoid follicles. Correct T cell localization within lymphoid follicles in the lung is required for maximal macrophage activation and Mtb control. Since IL-17 has a critical role in vaccine-induced immunity against TB, our results have far reaching implications for the design of vaccines and therapies to prevent and treat emerging Mtb strains. In addition, our data changes the existing paradigm that IL-17 is dispensable for primary immunity against Mtb infection, and instead suggests a differential role for IL-17 in early protective immunity against emerging Mtb strains. Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), infects one third of the world's population. Among these infections, clinical isolates belonging to the W-Beijing are emerging, representing about 50% of Mtb isolates in East Asia, and about 13% of all Mtb isolates worldwide. In animal models, infection with W-Beijing strain, Mtb HN878, is considered “hypervirulent” resulting in increased mortality. The proinflammatory cytokine Interleukin (IL)-17 is thought to be dispensable for primary immunity against Mtb infection. We report here that while IL-17 is dispensable for protection against infection with lab adapted Mtb strains such as H37Rv, or less virulent Mtb clinical isolates such as Mtb CDC1551, IL-17 is required for early protective immunity against Mtb HN878 infection. The dependence on IL-17 to drive protective immunity against Mtb HN878 is due to the differential ability to induce high levels of IL-1β through a TLR-2-dependent mechanism, driving potent IL-17 responses, induction of the chemokine CXCL-13 and localization of T cells within lung lymphoid follicles for maximal macrophage activation and Mtb control. Together, our data change the existing paradigm that IL-17 is dispensable for primary immunity against Mtb infection, and suggests a differential requirement for IL-17 in protective immunity against some emerging Mtb strains.


  • Open Access

    Recombination Signal Sequence-Associated Restriction on TCRδ Gene Rearrangement Affects the Development of Tissue-Specific γδ T Cells

    by Uzodinma N. Uche, Christopher R. Huber, David H. Raulet, Na Xiong

    Assembly of TCRα and TCRδ genes from the TCRα/δ locus is tightly controlled for the proper generation of αβ and γδ T cells. Of >100 shared variable gene segments in the TCRα/δ locus, only a few are predominantly used for the TCRδ gene assembly, while most are for TCRα. However, the importance and mechanisms of the selective variable gene rearrangement for T cell development are not fully understood. We report herein that the development of a tissue-specific γδ T cell population is critically affected by recombination signal sequence-associated restriction on the variable gene usage for TCRδ assembly. We found that the development of substitute skin γδ T cells in mice deficient of the TCRγ3 gene, which is used in wild-type skin γδ T cells, was drastically affected by the strain background. A Vγ2+ skin γδ T cell population developed in mice of the B6 but not the 129 strain backgrounds, due to a difference in the rearrangement of endogenous Vδ7+ TCRδ genes, which paired with the Vγ2+ TCRγ gene to generate the Vγ2/Vδ7+ skin γδ T cell precursors in fetal thymi of the B6 background mice. The defective TCRδ rearrangement of the 129-“Vδ7” gene was associated with specific variations in its recombination signal sequence, which renders it poorly compatible for rearrangement to Dδ genes. These findings provide the first direct evidence that recombination signal sequence-associated restriction on the variable gene usage for TCRα/δ gene assembly plays an important role in T cell development.